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Abstract
Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence of the
etiologic strains of Mycobacterium tuberculosis (M. tb), the aberrant host immune responses and the diminishing
treatment options with TB drugs. New treatment regimens incorporating therapeutics targeting both M. tb and
host factors are urgently needed to improve the clinical management outcomes of MDR-TB. Host-directed therapies
(HDT) could avert destructive tuberculous lung pathology, facilitate eradication of M. tb, improve survival and
prevent long-term functional disability. In this review we (1) discuss the use of HDT for cancer and other infections,
drawing parallels and the precedent they set for MDR-TB treatment, (2) highlight preclinical studies of pharmacological
agents commonly used in clinical practice which have HDT potential, and (3) outline developments in cellular therapy
to promote clinically beneficial immunomodulation to improve treatment outcomes in patients with pulmonary
MDR-TB. The use of HDTs as adjuncts to MDR-TB therapy requires urgent evaluation.
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Background
The World Health Organization (WHO) presently ranks
tuberculosis (TB) as the leading cause of death due to
infectious disease worldwide, with an estimated 1.5 million
deaths from TB in 2014 [1]. Multidrug-resistant TB
(MDR-TB) accounted for more than 3 % of newly diag-
nosed TB cases, and over 10 % (190,000) of all TB-related
deaths [1]. Further, 12 % of individuals diagnosed with TB
were also co-infected with HIV, comprising more than
20 % (390,000) of deaths due to TB in 2014 [1]. Current
WHO guidelines for MDR-TB treatment recommend
the use of combination TB drug therapies that target
Mycobacterium tuberculosis (M. tb). These drugs, sev-
eral of which have serious side effects, have to be taken
for a period of 12–18 months, with the long duration
resulting in poor patient compliance. Furthermore, current
MDR-TB treatment regimens cure only 50 % of MDR-TB
cases and impose a huge financial toll on national health
services [1, 2]. Other important limitations of current
MDR-TB treatment include drug interactions and insuffi-
cient drug concentrations in patients’ lungs [3] as well as
aberrant or excess host inflammatory responses to M. tb,
resulting in lung tissue destruction, compromising the
body’s ability to eradicate the M. tb bacilli, and leading to
permanent lung tissue damage [4–6].
Pulmonary pathology observed in patients with all
forms of TB can be attributed to intrinsic exaggerated
inflammatory responses to M. tb [4]. Since HIV co-
infection is the major comorbidity associated with
poor clinical outcome in patients with active TB, early
restoration of immune cells in HIV-TB patients following
antiretroviral therapy (ART) can result in the development
of immune reconstitution inflammatory syndrome (TB-
IRIS) [5]. In TB-IRIS, existing M. tb-specific T cells prolif-
erate uncontrollably, consequently perpetrating local and
systemic overt immune reactions and potentially leading
to death [5]. An exaggerated release of pro-inflammatory
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cytokines, such as tumour necrosis factor alpha (TNF-α),
interleukin 6 (IL-6), IL-8, IL-18, and interferons alpha and
beta (IFN-α/β), invariably perpetrate tissue damage in ac-
tive TB as well as TB-IRIS [6, 7]. Although TB-IRIS is
more closely associated with drug-susceptible TB patients
starting on ART, it has been reported in South African pa-
tients with MDR-TB and HIV co-infection [8]. An exigent
need therefore exists to develop new strategies to treat
and prevent harmful inflammatory responses in MDR/ex-
tensively drug resistant-TB patients to avoid long-term, if
not permanent, lung damage [9–12].
Considering these limitations and intricate clinical sce-
narios in TB, host-directed therapies (HDTs) have emerged
as a new and promising intervention avenue against all
forms (drug-sensitive and drug-resistant) of the disease
[13]. HDTs generally target clinically relevant biological
pathways in the host to modulate and rectify pathological
immune responses. In TB, HDTs may neutralise excessive
inflammation in organs and decrease M. tb proliferation
while facilitating tissue repair [7, 10].
Therapeutic targeting of immunological and
cellular processes in MDR-TB
Over the past several years, extensive preclinical and
clinical studies have revealed a myriad of immunological
pathways and biomarkers that either influence the out-
come of M. tb infection or indicate the state of disease,
respectively [6, 14–18]. These pathways include cytokine-
mediated signalling, intracellular antimicrobial processes,
and establishment of long-term immunological memory
as well as physiological homeostasis [13]. The use of im-
munomodulatory agents as HDTs for TB treatment has
therefore garnered great interest as a means of improving
clinical outcome of therapy, based on previous experience
with other infectious diseases and cancer. Many of these
agents are already licensed for non-TB indications, thus
bearing US Food and Drug Administration approval, while
others are in advanced clinical trials [18, 19]. A summary
of the various HDT agents with therapeutic potential in
pulmonary MDR-TB is presented in Table 1 and Fig. 1.
Immunomodulatory small-molecule drugs
Several non-antibiotic drugs with immunomodulatory
properties have already shown clinical efficacy in ameli-
orating infection-induced pathology. For example, inter-
ventional use of glucocorticoid receptor agonists, i.e.,
prednisone and dexamethasone, has mortality-reducing
effects in community-acquired pneumonia, concomitant
with lowering of pro-inflammatory cytokine release
[20, 21]. However, the clinical outcome of prednisone
therapy in pulmonary TB has been inconclusive; fur-
ther studies are required to ascertain a clear beneficial
effect in patients [22].
Eicosanoid regulation dependent on arachidonic acid
(ARA) metabolism has been associated with modulation
of clinically relevant immune responses and pathology in
patients with active TB [23]. Two major arms of enzymatic
reactions carry out ARA catabolism: the first involving
cyclooxygenases 1 and 2 (COX1 and 2) and the other,
lipoxygenases (LO). Breakdown of ARA by COX enzymes
progresses to prostaglandin synthesis, while LO metabolise
ARA to produce leukotrienes, lipid mediators responsible
for fever induction during active infection [24]. COX2 is
particularly associated with regulation of pro-inflammatory
cytokine production and inflammation via prostaglandin E2
(PGE2) production [25]. Leukotrienes are also involved in
initiation of inflammation, angiogenesis and progression of
cancer [25].
It has been shown in TB that balance between concen-
trations of lipoxin A4 (LXA4) and leukotrienne B4 con-
trols subsequent TNF-α release by activated immune cells
in the lung [23]. Overproduction of LXA4 may instead
cause immunosuppression, highlighting that maintenance
of this axis in TB is pivotal in determining patient survival
or death. The use of aspirin (acetylsalicylic acid), a non-
steroidal anti-inflammatory drug (NSAID) inhibits COX2
activity, thus enhancing LXA4 synthesis, which in turn
would decrease TNF-α levels and subsequently neutralise
pulmonary inflammation in TB patients [23, 26]. The
same may be achieved with ibuprofen (another NSAID),
which has been shown to improve survival of experimen-
tal mice with severe lung TB by dampening tissue path-
ology while reducing M. tb load [27]. Ibuprofen also has
direct anti-M. tb activity [28].
Zileuton is an anti-inflammatory drug currently licensed
for the treatment of asthma that exerts its effects by inhi-
biting 5-LO activity [29]. As opposed to NSAIDs, zileuton
blocks LO-mediated leukotriene production, facilitating
COX2 activation and PGE2 synthesis. In a mouse model
of TB, zileuton was shown to dramatically abate IFN-α/β
levels in the lung to improve lung pathology, in addition
to reducing M. tb load [30]. Combination therapy com-
prising zileuton and PGE2 augmented interleukin 1 beta
(IL-1β)-mediated control of M. tb growth. Furthermore,
patients with latent TB infection who successfully con-
tained infection and did not develop active pulmonary TB
appear to maintain balanced serum levels of PGE2 and
LXA4 [30].
In addition to their cholesterol-lowering properties,
statins also possess anti-inflammatory properties, which
enhance their efficacy in the clinical management of ath-
erosclerosis [31]. Statins can reduce IFN-γ-mediated
MHC-II upregulation, and thus CD4 T cell activation –
having clinical benefits in cardiac transplantation [32].
Statins may also downregulate TNF-α and IL-1β release
via activation of the transcription factor Kruppel-like
factor 2 (KLF2), as well as reduce IL-6, IL-8 and CCL5
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Table 1 List of immunomodulatory agents for the treatment of multidrug-resistant tuberculosis
Immunomodulatory
agent
Host target Currently licensed
indication(s)
Biological activity Ref.
Small molecules
Metformin AMPK activator Diabetes Augments mitochondrial reactive oxygen species-
mediated intracellular MDR M. tb killing and reduction
of lung bacterial burden and pathology in mice likely
via increased mitochondrial turnover; enhances CD8 T
cell responses, possibly by increasing FAO with AMPK
involvement in memory cells. Shown to promote anti-
tumour CD8 T cell memory generation in engrafted
TNF receptor associated factors knockout mice via
FAO restoration
[41, 43, 120]
Zileuton 5-lipoxygenase
inhibitor
Asthma Inhibits 5-lipoxygenase and subsequent formation of
leukotrienes; promotes reduced lung M. tb burden
and pathology in mice by increasing PGE2 levels
and augmenting IL-1β-mediated anti-TB immune
control
[29, 30]
Ibuprofen COX inhibitor Pain and fever relief Inhibits COX2 and suppresses prostaglandin H2 and
thromboxane production; inhibits COX1; reduces
lung pathology and M. tb load in a highly-
susceptible TB mouse model
[27]
Aspirin
(acetylsalicylic acid)
COX inhibitor Pain and fever relief Inhibits COX1 to suppress prostaglandin and
thromboxane production to dampen TNF-α-induced
overt inflammation; aids tissue repair and control of
M. tb burden
[121]
Valproic acid Histone deacetylase
inhibitor
Epilepsy and bipolar
disorder
Inhibits HDAC I, II and IV to block histone
deacetylation and enhance gene transcription;
activates latent HIV reservoirs and increases ART
efficacy as well as increased CD8 T cell activity; can
induce autophagy and apoptosis
[61, 122, 123]
Carbamazepine GABA receptor agonist
and sodium channel
stabiliser
Epilepsy and
neuropathic pain
Induces autophagy via inositol depletion in
macrophages, potentiating killing of intracellular
M. tb; reduces lung pathology and improves overall
immune responses in a mouse model of TB
[124]
Vorinostat Histone deacetylase
inhibitor
Cutaneous T cell
lymphoma
Inhibits HDAC I, II and IV to block histone
deacetylation and enhance gene transcription;
induces reactivation of latent HIV in CD4 T cells and
improves CD8 T cell responses as well as ART
efficacy – presently in clinical trials in HIV-infected
individuals; can induce autophagy and apoptosis;
shown to dampen neuroinflammation in a mouse
model of West Nile virus infection, adjunctively to
an experimental antiviral drug candidate
[62, 69, 125–127]
Phenylbutyrate Histone deacetylase
inhibitor, chemical
chaperone
Urea cycle disorders Inhibits HDAC I to block histone deacetylation and
enhance gene transcription; induces autophagy by
activating expression of antimicrobial peptides by
macrophages to kill intracellular M. tb in combination
with vitamin D3; shown to be very beneficial as
short-course therapy (with vitamin D3) in a clinical
study involving patients with pulmonary TB
[70, 71, 127, 128]
Cyclophosphamide DNA alkylating agent Lymphomas and
pre-transplant
preconditioning
Forms lethal phosphoramide mustard following
activation specifically in low producers of aldehyde
dehydrogenase (largely Tregs); activity shown to
potentiate renal cell carcinoma clinical vaccine
candidate; Treg depletion may imply clinically
beneficial immune responses in severe pulmonary TB
[49, 51, 82, 85, 129]
Etoposide Topoisomerase
inhibitor
Various cancer types Inhibits DNA topoisomerase I activity to abrogate
cell proliferation; depletion of pathogenic inflammatory
T cells in influenza-induced hemophagocytic
lymphohistiocytosis shown to be beneficial
[130]
Imatinib mesylate Tyrosine kinase
inhibitor
Leukaemias and
gastrointestinal stromal
tumours
Inhibits mutant BCR-ABL tyrosine kinases in cells;
reduces colony forming unit load and pathology in
lungs of M. tb-infected mice; induces myelopoiesis
[44, 45]
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Table 1 List of immunomodulatory agents for the treatment of multidrug-resistant tuberculosis (Continued)
Niraparib PARP inhibitor Ovarian and breast
cancers
Inhibits PARP1/2 to cause double strand DNA breaks
in cells, abrogating proliferation; niraparib has been
shown to restore mitochondrial respiration in human
muscle fibres, likely by improving FAO, thus promoting
maintenance of anti-TB memory CD8 T cells
[131]
Prednisone Glucocorticoid receptor
agonist
Immunosuppressant
used in cancer and
inflammatory diseases
Activated downstream signalling of the GC receptor;
has pleiotropic outcomes, including anti-inflammatory
effects; use in community-acquired pneumonia
showed improved survival among patients; results in
TB patients inconclusive and requires further validation
[20, 22, 132]
Nutraceuticals
Resveratrol Sirtuin agonist Over-the-counter
antioxidant
Increases cellular mitochondrial turnover, thus
increased respiratory capacity; may promote
maintenance of anti-TB memory CD8 T cells via FAO
increase; alternatively, may also induce apoptosis of
activated T cells during severe inflammation
[120, 133]
Vitamin D3 Innate immune
response activator
Dietary supplement Kills intracellular M. tb; activates innate immune
responses in macrophages, thus improving ensuing
T cell responses in combination with phenylbutyrate;
also augments IL-32 and IL-15-mediated immune
responses in clinical TB
[70, 71, 85, 86, 88,
128, 134]
Biologicals
Interleukin 15 Involved in CD8
memory T cells
maintenance
In clinical trials for
various cancers
Signals via IL-15Rβ and the common chain to activate
STAT3 and STAT5; increases mitochondrial mass and
fatty acid oxidation in memory CD8 T cells to prolong
survival and maintenance; augments IFN-γ and
vitamin D3-mediated immune responses in human TB
[86, 135, 136],
NCT01727076
Nivolumab/
pembrolizumab
(anti-PD-1)
Immune checkpoint
inhibitor
Melanoma; in clinical trials
for various other cancers
Inhibits PD-1 expressed on T cells, and abrogates
interaction with PD-L1 on tumour cells and myeloid
cells to reverse T cell exhaustion increases tumour-
specific CD8 T cell activity and tumour regression in
metastatic melanoma patients; highly expressed on
Tregs isolated from peripheral blood of MDR-TB
patients; in vitro blockade of PD-1 on T cells from TB
patients potentiated M. tb antigen-dependent IFN-γ
secretion; anti-TB treatment success is commensurate
with lower PD-1 expression in patients
[137–140]
Ipilimumab
(anti-CTLA-4)
Immune checkpoint
inhibitor
Melanoma; in clinical
trials for various other
cancers
Inhibits CTLA-4 expressed on T cells, abrogates
interaction with CD80 and/or CD86 on tumour cells
and myeloid cells to reverse T cell exhaustion; increases
CD8 T cell activity and tumour regression in melanoma
patients; highly expressed on Tregs isolated from
peripheral blood of MDR-TB patients; may potentiate
cellular immune responses in clinical TB
[141]
Anti-LAG3 Immune checkpoint
inhibitor
In clinical trials for
various cancers
Inhibits LAG3 expression; blockade of LAG3 can
prevent T1DM development in mice, potentiate CD8
T cell activity of a prostate cancer vaccine candidate
and enhance antimalarial immune responses; in
non-human primate models of TB, LAG3 expression
on CD4 T cells has been shown to correlate with
poor anti-TB immune function; blocking LAG3 may
contribute to successful containment of TB infection
by T cells
NCT02460224,
NCT02061761, [106]
Adalimumab
(anti-TNF-α)
Cytokine neutralisation Rheumatoid arthritis Removes excess TNF-α from systemic circulation and
target organs; successfully used as salvage therapy
in a patient with severe pulmonary TB
[72]
Siltuximab (anti-IL-6) Cytokine neutralisation Juvenile arthritis,
Castleman’s disease
Removes excess IL-6 from systemic circulation and
target organs; use in MDR-TB patients co-infected
with HIV may aid in management of ART-induced
TB-IRIS
[6, 74, 142, 143]
Tocilizumab
(anti-IL-6R)
Cytokine signalling
blockade
Arthritis, Castleman’s
disease
Prevents IL-6 from binding to its receptor on cell
surfaces to reduce pro-inflammatory signalling; use
[6, 74, 142, 143]
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Table 1 List of immunomodulatory agents for the treatment of multidrug-resistant tuberculosis (Continued)
in MDR-TB patients infected with HIV may aid
in management of ART-induced TB-IRIS
Bevacizumab
(anti-VEGF)
Angiogenesis inhibitor Various cancer types
(mostly solid tumours)
Inhibits binding of VEGF-A to its receptor to block
signalling and subsequent formation of new blood
vessels; bevacizumab inhibited neovascularisation
and improved lung pathology in a rabbit model of TB;
may also facilitate drug penetration into granulomas
and increased oxygenation, with implications for
enhancing anti-TB drug efficacy
[79, 144]
Cellular therapy
Bone marrow-
derived mesenchymal
stromal cells
Reduction of
inflammation and
improved tissue
regeneration
In clinical trials for
various inflammatory
indications
Successful phase 1 safety study of mesenchymal
stromal cell reinfusion into patients with MDR/
extensively drug resistant-TB in Belarus; showed
improved lung radiographic findings, pulmonary
function (57 % cure); promoted fine-tuning of T cell
responses to specific M. tb antigens in recipients; trial
is currently being repeated in Durban, South Africa
[112, 114, 145]
Antigen-specific
T cells
Targeted killing of M.
tb-infected host cells
Cancer and viral
infections
Currently used in cancer immunotherapy; successfully
used in treating post-transplantation opportunistic
viral infections, i.e. cytomegalovirus, Epstein–Barr virus
[111–113, 115,
116, 118, 146]
ART antiretroviral therapy, IRIS immune reconstitution inflammatory syndrome, FAO fatty acid oxidation, HDAC, Histone deacetylase inhibitors, MDR multidrug
resistant; M. tb Mycobacterium tuberculosis, TB tuberculosis
Fig. 1 Host-directed therapies aimed at modulating immune responses in the tuberculous lung. Overt immune responses characterise the
pathological outcome in tuberculosis (TB). Neutralisation of pro-inflammatory cytokines such as IL-6, TNF-α, VEGF and IFN-αβ, as well as
anti-inflammatory IL-4 during severe pulmonary disease may help reduce ongoing parenchymal damage in the lung. Alternatively, suboptimal
activation of anti-TB immune responses due to regulatory T cell activity can be reversed by the use of the anti-cancer drug cyclophosphamide. Drugs
with anti-TB potential, such as metformin, imatinib, ibuprofen, zileuton, valproic acid, and vorinostat as well as nutraceuticals such as vitamin D3 not
only abate bacterial burden via host-dependent mechanisms, but may also fine-tune the immune response to Mycobacterium tuberculosis (M. tb). These
drugs increase phagocytosis of extracellular bacteria, improved emergency myeloid response and increased autophagic and apoptotic killing
of bacteria, subsequently editing the T cell response in favour of the host. Immune checkpoint inhibition with blockade of the PD-1/PD-L1,
CTLA-4, LAG3 and TIM3 pathways may improve the quality of the cellular immune response to M. tb epitopes, as seen in cancer. A more
complete list of currently pursued host-directed therapies for TB can be found in Table 1. Abbreviations: VPA, valproic acid; PBA, phenylbutyrate; PD-1,
programmed cell death 1; PD-L1, PD-1 ligand 1; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; LAG3, lymphocyte-activation gene 3; TIM3, T cell
immunoglobulin and mucin domain 3
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secretion by myeloid cells and lymphocytes [31]. Prior use
of statins has been shown to ameliorate inflammation-
induced organ damage, thus reducing mortality among pa-
tients with sepsis and community-acquired pneumonia
[33–36]. The therapeutic potential of statins has been eval-
uated in TB. Peripheral blood mononuclear cells derived
from patients with familial hypercholesterolemia undergo-
ing atorvastatin therapy were found to be more resistant to
M. tb infection and replication [37]. It was established in a
mouse model of TB that the cholesterol-lowering proper-
ties of atorvastatin potentiated this effect, where simvastatin
treatment was concomitant with reduced pulmonary, hep-
atic and splenic M. tb burden and tissue pathology [37]. It
was also shown that simvastatin potentiates autophagic cell
death of M. tb-infected macrophages, thus having a dual
approach in controlling TB disease. In a separate study, co-
administration of simvastatin to an anti-TB chemotherapy
regimen combining rifampicin, isoniazid and pyrazinamide
led to improved bactericidal activity of the drugs against
intracellular M. tb as well as in a mouse model of TB [38].
Clinically, patients with type 2 diabetes mellitus (T2DM)
on statin therapy (as well as anti-diabetic therapy) seem to
be at lower risk of developing active TB [39].
Metformin (MET) is an essential drug used in the
treatment of T2DM, which acts by affecting the mito-
chondrial respiratory chain [40]. In a recent preclinical
study, MET was evaluated as an adjunct therapeutic
for drug-susceptible (DS)-TB and MDR-TB [41]. MET
treatment induced superoxide anion production in
macrophages infected with DS or MDR M. tb in an-
adenosine monophosphate-activated protein kinase
(AMPK)-dependent manner [41]. Furthermore, MET
therapy potentiated the activity of the first-line anti-TB
drugs isoniazid and ethionamide in a mouse model of TB,
commensurate with improved anti-TB CD8 T cell re-
sponses, reduced concentrations of inflammatory cyto-
kines and lung pathology [41]. A retrospective evaluation
of patients with T2DM receiving MET therapy showed
that they are less prone to develop cavitary pulmonary TB.
In addition, T cell non-reactivity to ESAT-6 in a T-SPOT
IFN-γ assay also suggested less incidence of latent TB
infection among these individuals [41]. The ability of
MET to promote maintenance of memory CD8 T cells
via AMPK-driven fatty acid oxidation, as seen in mouse
models of solid tumours [42, 43], may be an additional
avenue for its potent immunomodulatory properties in TB.
Imatinib mesylate, a highly specific and successful
drug that inhibits the Bcr-Abl tyrosine kinase in chronic
myelogenous leukaemia has also been evaluated in TB
[44]; treatment of M. marinum-infected mice with ima-
tinib resulted in enhanced myelopoiesis in the bone
marrow. Furthermore, an early influx of neutrophils
into the lungs of infected mice helped reduce the bac-
terial burden. Imatinib in combination with rifampicin
greatly reduced liver pathology in mice infected with
M. marinum, while reducing lung bacterial load also in
M. tb-infected animals [45].
The DNA alkylating agent cyclophosphamide (CP) is a
potent anti-proliferative cancer drug and pre-conditioning
agent metabolised by cytochrome P450 to produce reactive
metabolites that crosslink with guanine residues [46, 47].
Cell types expressing low amounts of aldehyde dehydro-
genase are most susceptible to CP treatment since its
enzymatic activity neutralises drug-derived cytotoxicity
[48]. Regulatory T cells (Tregs) express high cellular
levels of ATP-binding cassette B1, which binds CP, thus
making these cells especially vulnerable to the drug
[49]. Conversely, aldehyde dehydrogenase overexpression
can promote resistance to CP toxicity [50]. Prior CP admin-
istration to patients participating in a clinical trial of a renal
cell cancer vaccine candidate (IMA901) led to Treg decline
in peripheral blood of the participants, afforded better CD8
T cells priming and improved overall survival [51]. CP
treatment may remove Treg cells as well as pathological
lymphocytosis in patients with MDR-TB [52–54].
Histone deacetylase inhibitors (HDIs) comprise several
clinically approved pharmacological agents which block
the activity of the chromosome-modifying enzymes his-
tone deacetylases to promote gene transcription [55].
Histone acetylation mediated by HDIs has been clinically
beneficial in cancer therapy [56], vorinostat (suberoylanilide
hydroxamic acid) was licensed in 2006 for the treatment of
cutaneous T cell lymphoma [57], and valproic acid (VPA,
currently in use for epilepsy and bipolar disorder) is in clin-
ical trials for solid tumours [58], while many others are in
late-stage clinical trials for a plethora of cancers [59]. VPA
and vorinostat can induce apoptosis and autophagy in
treated cells via oxidative burst and inhibition of the mam-
malian target of rapamycin (mTOR), respectively [60–62].
The effectiveness of HDIs in infectious disease has been
evaluated against HIV infection and West Nile virus in-
fection. VPA or vorinostat treatment of CD4 T cells
from individuals latently infected with HIV-1 can reactivate
viral progeny, making virus-infected cells highly susceptible
to ART as well as CD8 T cell-mediated immune attack
[63–66]. These observations have led to investigating the
clinical efficacy of HDIs in HIV-infected individuals
[67, 68]. In a mouse model of West Nile virus infection,
co-treatment of vorinostat with an experimental anti-
viral drug candidate ameliorated brain inflammation
and neuronal damage in addition to reduction in viral
load [69]. Evaluation of phenylbutyrate (PBA), another
HDI, against intracellular M. tb has been shown to potenti-
ate pro-inflammatory signalling (upregulation of CASP1,
IL12, and VDR genes, among others), antimicrobial peptide
production, reducedM. tb survival, thus implying enhanced
anti-TB T cell activity [70]. Clinical evaluation of PBA and
vitamin D3 treatment in patients with pulmonary TB
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resulted in quicker sputum smear conversion and in-
creased production of cathelicidin by peripheral blood
monocyte-derived macrophages [71].
Blockade of cytokine signalling
As previously mentioned, the uncontrolled release of
pro-inflammatory cytokines, such as TNF-α, IL-6 and
IFN-α/β, drives destructive immunopathology and severe
lung disease in TB. The use of anti-TNF-α therapy (ada-
limumab) in a patient with severe pulmonary TB proved
to be life-saving [72], and set the stage for anti-cytokine
therapy in clinical management of TB. IL-6, a major
player in exacerbating disease severity in patients with
TB, is another potential candidate for clinical blockade
[6, 73], further confirmed by reduction of IL-6 serum
levels in TB patients post-treatment [74]. Preclinical
evaluation of IL-6 receptor (IL-6R) blockade in a mouse
model of TB improved specific anti-TB T cell responses
in conjunction with less severe pathology and reduced
M. tb burden in the lungs [75]. Monoclonal antibodies
that inhibit the IL-6/IL-6R pathway are currently en-
dorsed for treatment of immune-mediated diseases such
as idiopathic juvenile arthritis and Castleman’s disease in
humans (anti-IL-6, siltuximab; anti-IL-6R, tocilizumab)
[76, 77], and are currently under investigation for cancer
treatment [78]. Blockade of the IL-6/IL-6R pathway may,
therefore, be considered for clinical management of
severe pulmonary MDR-TB. Preclinical evaluation of
bevacizumab (anti-vascular endothelial growth factor
(VEGF) monoclonal antibody) in a rabbit model of TB
showed that inhibition of VEGF-A was commensurate
with modified angiogenesis in the granuloma, which
improved penetration of a small molecule dye (repre-
sentative of an anti-TB drug) as well as oxygenation
[79]. Oehlers et al. [80] showed that VEGF promotes
granuloma formation in M. marinum-infected zebrafish,
while pharmacological inhibition of VEGF activity with
pazopanib reduced neovascularisation as well as the myco-
bacterial burden in the animals. IL-4 is another cytokine
associated with poor prognosis in clinical TB that quanti-
tatively declines in response to anti-TB treatment [81–84].
A clinical trial investigating the adjunctive potential of IL-
4 blockade (anti-human IL-4 monoclonal antibody, pasco-
lizumab) in patients with DS pulmonary TB undergoing
anti-TB treatment is currently underway (NCT01638520).
Vitamin D3
Vitamin D3 (VD3) is important for host resistance to
TB; pulmonary TB patients with VD3 deficiency are not
able to mount adequate control of primary M. tb infec-
tion in the lung [85]. Further, VD3 has been implicated
in immunological control of TB in humans involving or-
chestration of IFN-γ, IL-32 and IL-15 signalling [86, 87].
Recent evaluation of the therapeutic potential of VD3
in combination with PBA has shown improved anti-
mycobacterial effects and faster conversion to AFB-
negative sputum by the participating TB patients [71].
In vitro evaluation of M. tb-infected macrophages
treated with VD3 resulted in upregulation of a collage
of anti-inflammatory (IL-10, ARG1) and pro-inflammatory
(IL1B, TNF) genes over a 72-hour exposure period [70] –
this profile was relatively unchanged with PBA co-
treatment. However, other clinical studies have not found
a correlation between VD3 therapy and improved treat-
ment outcome in TB patients [88, 89]. The therapeutic
potential of VD3 in MDR-TB patients therefore warrants
further clinical evaluation in larger cohorts of patients in
endemic countries.
Immune checkpoint inhibition
One of the most remarkable immunomodulatory therap-
ies of recent times is currently licensed for melanoma
treatment – antibody-based inhibition of the immune
checkpoints programmed cell death 1 (PD-1) and cyto-
toxic T lymphocyte-associated antigen 4 (CTLA-4). This
strategy activates and mobilises tumour-infiltrating T lym-
phocytes as well as those in peripheral blood of patients
with metastatic melanoma [90]. Although immunologically
purposed to regulate T cell responses for avoiding immune
hyper reactivity, PD-1 and CTLA-4 expression on tumour-
specific T cells abrogates anti-tumour effector functions
and renders the T cells irresponsive [91]. Tregs have abun-
dant expression of PD-1 on their surface; interaction of this
molecule with its ligands (PD-L1/2) on target cells leads to
expansion and dampening of antigen-specific effector T cell
responses [92]. Importantly, a myriad of cytokines, includ-
ing IFN-γ, TNF-α, type 1 interferons, GM-CSF, IL-2, IL-7
and IL-15, are actively involved in enhancing the expression
of PD-1 on T cells and its ligands on antigen-presenting
cells and tumour cells at sites of disease [93]. CTLA-4
binds to CD80 and/or CD86 to control the activation state
of effector T cells in the aftermath of a successful immune
response, and initiates tolerance by abrogating IL-2 produc-
tion and downstream activation of signal transducer and
activator of transcription 5 (STAT5) [94].
Results from clinical trials assessing monoclonal anti-
bodies targeting PD-1 (pembrolizumab/nivolumab) and
CTLA-4 (ipilimumab) in cancers other than melanoma,
i.e., lung cancer and ovarian cancer, have been very
promising [95, 96]. Anti-PD-1 therapy (nivolumab) has
been fruitful also in treating patients with chronic
hepatitis C virus infection, resulting in a dramatic re-
duction in viral load [97]. There are several ongoing
clinical studies evaluating the efficacy of anti-PD-L1
therapy (avelumab, MEDI4736) in cancer (e.g., but not
limited to, NCT02572843, NCT02584829, NCT02588131,
NCT02088112). Several clinical studies have evaluated the
role of the PD-1/PD-L1 pathway in the pathogenesis of
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TB. PD-L1, the main ligand for PD-1, is markedly
expressed on human macrophages upon infection with
virulent M. tb [98]. In vitro blockade of PD-L1 with
monoclonal antibodies induced IFN-γ-triggered killing
of the infected cells by autologous peripheral blood T
cells from patients with pulmonary TB [98, 99]. Clinic-
ally, PD-1 expression on T cells declines over a course
of standard anti-TB therapy – concordant with im-
proved in vitro responsiveness of Th1 cells to antigenic
stimulation [99, 100]. In addition, expression of PD-1
on the surface of neutrophils, Tregs and natural killer
T cells indicates that destructive inflammation in TB
patients may further impair the M. tb-specific immune
response [53, 54, 101, 102]. Similar observations have
been reported for CTLA-4 expression on Tregs and ef-
fector T cells isolated from peripheral blood of patients
with active TB [53, 103, 104].
Lymphocyte-activation gene 3 (LAG3) is another im-
mune checkpoint generally expressed by Tregs to modu-
late CD4+ T cell responses, and binds to MHC-II
molecules with high affinity to induce T cell exhaustion
several days after activation [105]. LAG3 was recently
shown to be highly expressed in the lungs of macaques
with active pulmonary TB and not in latent TB infec-
tion, suggesting a link between low LAG3 expression
and successful containment of M. tb infection [106].
Combined blockade of PD-1 and LAG3 is able to rescue
specific CD4+ and CD8+ T cell activity directed against
Plasmodium falciparum in an experimental mouse
model of malaria [95, 107]. Several clinical trials are
currently registered for testing the efficacy of anti-
LAG3 monoclonal antibodies (BMS-986016, GSK2831781,
LAG525) in various cancers (NCT02061761, NCT01968109,
NCT02195349, NCT02460224).
The fourth clinically relevant immune checkpoint
molecule is T cell immunoglobulin and mucin domain
3 (TIM3). Immunologically, TIM3 binds to galectin 9
(Gal9) on the surface of antigen-presenting cells (as
well as tumour cells) to induce apoptosis of activated T
cells [108]. Inhibition of TIM3 (MBG453) in cancer
therapy affords improvement of anti-tumour T cell re-
sponses, marked by IFN-γ secretion and CD8 T cell ef-
fector functions [108]. Pertinent to TB, in vitro TIM3
blockade in co-culture experiments with M. tb-infected
macrophages from TB patients with or without HIV
co-infection fostered bacterial killing and enhanced IL-
1β secretion by infected cells as well as IFN-γ release
by T cells [109, 110]. T cell-mediated reduction of bac-
terial burden in infected macrophages from HIV-TB
patients was further improved in combination with
anti-PD-1 blockade [110]. Along with PD-1 and CTLA-
4, treatments targeting LAG3 and TIM3 may improve
targeted immune responses in patients with MDR-TB
for better clinical outcomes.
Cellular therapy
In addition to chemical compounds, monoclonal anti-
bodies and nutraceuticals, cell-based therapies have also
been very promising in cancer and infectious disease
[111, 112]. Adoptive transfer of tumour-infiltrating T
lymphocytes has saved many lives in the last 20 years,
with objective response rates reaching 56 % in patients
with metastatic melanoma [113]. Transfer of donor-
derived cytomegalovirus- and Epstein–Barr virus-specific
CD8 T cells following stem cell transplantation is actively
pursued in the clinic [111]. Pertaining to TB, re-infusion
of bone marrow-derived mesenchymal stromal cells
isolated from patients with MDR/extensively drug
resistant-TB was shown to be safe [114], and a phase 2
trial is underway in Durban, South Africa, to evaluate
their efficacy in improving treatment outcomes and ef-
fects on immune responses. Mesenchymal stromal cell
treatment also re-programmed anti-TB T cell responses,
with focus on specific M. tb antigens. Infusion of M. tb-
specific T cells has yet to be clinically evaluated in TB pa-
tients, although in vitro evidence for feasibility, comprising
subsets of CD8 T cells, NK T cells and TCR γδ T cells, has
been established [115–119].
Conclusion
The poor treatment outcomes of MDR-TB treatment
using current WHO recommended TB drug treatment
regimens now warrants newer approaches to therapy.
The use of immunomodulatory agents as adjunct HDT
for improving management outcomes warrants urgent
evaluation in well designed, controlled randomized clin-
ical trials. These studies will also provide opportunities
to study the M. tb-specific immune responses in the
lung and peripheral blood (B cells, T cells, macrophages,
antibodies) as markers of inflammation, disease activity,
cure or relapse. Well-designed, multicentre randomised
clinical trials involving aptly defined patient cohorts are
now required.
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